Evotec (NASDAQ:EVO) Hits New 12-Month Low at $5.10

Evotec SE (NASDAQ:EVO) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $5.10 and last traded at $5.18, with a volume of 512534 shares traded. The stock had previously closed at $7.65.

Analyst Ratings Changes

A number of brokerages have issued reports on EVO. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a report on Thursday, January 18th. HC Wainwright cut their price target on Evotec from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.

Evotec Trading Down 2.5 %

The stock has a fifty day moving average price of $7.33 and a two-hundred day moving average price of $8.67.

Institutional Investors Weigh In On Evotec

Hedge funds have recently made changes to their positions in the business. Mubadala Investment Co PJSC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $53,931,000. Optiver Holding B.V. increased its stake in shares of Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the period. Finally, Quadrant Capital Group LLC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $25,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.